Abstract: The disclosure relates to a composition for labeling a target lesion, in form of microspheres including a biocompatible polymer; and a dye for biological tissue, and directly administered to a target lesion to confirm size and location of the target lesion in real time during surgery at a target site and a method preparing the same. The composition for labeling a target lesion of the present disclosure, when injected into a target lesion, remains there for several months and can detect the location and size of the labeled lesion in real time during surgery, thereby not only improving the success rate of surgical operation for the target lesion, but also preventing excessive loss of normal tissue, and therefore can be widely utilized as an effective surgical marker.

Abstract: Provided is a kit or a device for the detection of pancreatic cancer, including a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, including measuring the miRNA(s) in vitro.

Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.

Abstract: The present invention provides an alginic acid-based injectable hydrogel system for labeling an accurate position of a disease lesion and effectively delivering a drug to a target region. The formulation of the present invention can make it easy to locally inject a contrast agent and a drug into a target region while controlling the release rate of the contrast agent or the drug, with the formation of the hydrogel in the injected region. Through the advantages, the labeled position can be accurately determined from images, thereby enhancing the precision of surgical operation, with a minimal incision formed therefor. In addition, when used, the alginic acid-based injectable hydrogel system allows the effective local delivery of a drug to a target region while increasing the long-acting effect of the drug.

Abstract: A method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing evaluation items including combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8+ T cells in tumor tissue or blood.

Abstract: An embodiment according to the present invention provides a kit or device for detection of bladder cancer, and a method for detecting bladder cancer. An embodiment according to the present invention relates to: a kit or device for detection of bladder cancer, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting bladder cancer, including measuring the miRNA(s) in vitro.

Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.

Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.

Abstract: A method of measuring a speed of blood flow from a radio frequency (RF) signal, including decomposing a complex signal converted from the RF signal into base signals using singular value decomposition, classifying the base signals into a clutter signal, a blood flow signal, and a noise signal, separating a clutter region and a blood flow region from the classified clutter signal and blood flow signal, obtaining an output signal by removing the blood flow signal from the clutter signal in the clutter region and by removing the clutter signal from the blood flow signal in the blood flow region, and measuring a speed of the blood flow by calculating speckle decorrelation from the output signal.

Abstract: The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agenst capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.

Abstract: An endoscope system includes: an endoscope including an elongated portion in which an imaging optical system is arranged; an arm supporting the endoscope; and a unit capable of changing a field-of-view direction of the endoscope, wherein each library data stored in a storage includes a parameter related to relative position and attitude between the imaging optical system and an observation object, the parameter includes a first parameter or a second parameter, the first parameter determined by a sum of an inclination of a longitudinal axis of the elongated portion and an amount of curvature of the changing unit on base coordinates, the first parameter related to an orientation of the imaging optical system on the base coordinates, the second parameter indicating an orientation of the imaging optical system as viewed from a coordinate of the observation object, and the unit or the arm based on the library data is controlled.

Abstract: This invention provides a kit or a device for the detection of pancreatic cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, comprising measuring the miRNA(s) in vitro.

Abstract: Disclosed is a method for controlling an information processing apparatus configured to analyze a sequence of nucleic acid obtained from a specimen of a subject, the method including: obtaining, on the basis of a plurality of first reads read by a sequencer, a result of mutation detection in an analysis target region in the sequence of the nucleic acid; generating, on the basis of second reads, out of the first reads, that correspond to at least one predetermined site selected from a base sequence in the analysis target region, information regarding a quality of a nucleic acid analysis with respect to the predetermined site; and outputting the information regarding the quality, irrespective of presence or absence of a mutation at the predetermined site.

Abstract: This application provides a kit or a device for detection of ovarian tumor, comprising a nucleic acid(s) for detecting a miRNA(s) in a sample from a subject, and a method for detecting ovarian tumor, comprising measuring the miRNA(s) in vitro.

Abstract: The present invention relates to a composition for repressing the sternness of stem cells, which comprises a material for regulating OCT4 modification. The material for regulating OCT4 modification according to the present invention may regulate the phosphorylation or methylation of OCT4 and inhibit Wnt signaling, thereby effectively reducing the sternness of various stem cells. Therefore, since it can be effectively used in inhibition of proliferation, recurrence and metastasis of cancer, and inhibition of resistance to an anticancer agent, and can reduce sternness even in normal stem cells, it is expected that the time for differentiation of embryonic stem cells into specific cells is shortened, and efficiency is increased.

Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.

Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.

Abstract: Near-infrared fluorescent dye-loaded microspheres and a formulation thereof that include a complex of a near-infrared fluorescent dye and human serum albumin or cyclodextrin loaded into polymer microspheres, optionally with a hydrogel polymer. The near-infrared fluorescent dye-loaded microspheres are used in a method of marking lesions for accurately identifying the location of lesion sites from fluorescence imaging during surgery. The method involves injecting the microspheres into lesion sites in a subject, such as cancer. The intensity of fluorescence generated from the microspheres is stronger than that when microspheres are prepared using a near-infrared fluorescent dye alone, the stability of the fluorescent dye in the microspheres is improved, and the marked sites can be identified through fluorescent imaging for a long period of time, increasing the accuracy of surgery for lesion excision, and shortening the time required for surgery.

Abstract: An information processing apparatus (2000) detects an abnormal region (30) in each of a plurality of video frames (14) constituting video data (12) in which the inside of a body is captured. The information processing apparatus (2000) outputs output information related to the detected abnormal region (30). Herein, the information processing apparatus (2000) starts outputting of the output information when a detection score based on a proportion of the number of the video frames (14) in which the abnormal region (30) is detected becomes equal to or more than a first threshold value in a state where outputting of the output information is not being performed. Further, the information processing apparatus (2000) ends outputting of the output information when the detection score becomes equal to or less than a second threshold value in a state where outputting of the output information is being performed.

Abstract: An information processing apparatus (2000) detects an abnormal region (30) in each of a plurality of video frames (14) constituting video data (12) in which the inside of a body is captured. The information processing apparatus (2000) outputs output information related to the detected abnormal region (30). Herein, the information processing apparatus (2000) starts outputting of the output information when a detection score based on a proportion of the number of the video frames (14) in which the abnormal region (30) is detected becomes equal to or more than a first threshold value in a state where outputting of the output information is not being performed. Further, the information processing apparatus (2000) ends outputting of the output information 10 when the detection score becomes equal to or less than a second threshold value in a state where outputting of the output information is being performed.